Indoco Remedies

** Shares of India's Indoco Remedies INRM.NS jump as much as 16.76% to 267 rupees, its highest intraday pct gain since March 3, 2025

** Stock last up 11.71% at 255.46 rupees

** Co's fourth quarter net loss narrows to 216.4 million rupees ($2.29 million) from 403.9 million rupees a year ago

** Q4 revenue rises 18.75% y/y to 4.56 billion rupees

** Trading vols at 964,357 shares, about 20 times the 30-day average

** YTD stock down 2.52%

($1 = 94.3987 Indian rupees)

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

April 30 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - APPROVED PROPOSAL FOR TRANSFER OF BUSINESS THROUGH ATB WITH SUNWAYS FOR SALE AND TRANSFER OF COMPANY'S OPHTHALMIC BUSINESS

• INDOCO REMEDIES LTD - DEAL VALUED AT 1.10 BILLION RUPEES

Source text: ID:nBSE9QHG3y

Further company coverage: INRM.NS

(([email protected];))

** Shares of Indoco Remedies INRM.NS rise as much as 7.7% to 227.85 rupees, its highest since Feb. 6; last up 4.5%

** Stock up for ninth straight session

** Co says the U.S. Food and Drug Administration completed pre-approval inspection at testing facility in Aurangabad

** Inspection concluded with zero form 483 observations, co says

** More than 71,438 change hands vs 30 day avg of 49,098 shares

** YTD stock down 5.6%

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

April 13 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - U.S. FDA COMPLETED PRE-APPROVAL INSPECTION AT TESTING FACILITY IN CHHATRAPATI SAMBAJI NAGAR

Source text: [ID:]

Further company coverage: INRM.NS

(([email protected];))

** Shares of Indoco Remedies INRM.NS up 4.8% at 209.33 rupees

** Pharma co receives final Abbreviated New Drug Application (ANDA) approval from the USFDA for its anticonvulsant drug Brivaracetam Oral Solution

* The drug is a biosimilar for Briviact, made by Belgium-based UBC Pharmaceuticals

** More than 162,827 change hands vs 30 day avg of 65,246

shares

** YTD stock down 14.8%

(Reporting by Mridula Kumar in Bengaluru)

(([email protected];))

Feb 3 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - DEC-QUARTER CONSOL NET LOSS 297.9 MILLION RUPEES

• INDOCO REMEDIES LTD - DEC-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 4.45 BILLION RUPEES

Source text: [ID:]

Further company coverage: INRM.NS

(([email protected];;))

Jan 30 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - RECEIVES FINAL ANDA APPROVAL FOR LACOSAMIDE ORAL SOLUTION

Source text: ID:nBSEFvfNf

Further company coverage: INRM.NS

(([email protected];;))

Dec 11 (Reuters) - Indoco Remedies Ltd INRM.NS:

• RECEIVES EIR FROM USFDA FOR API FACILITY

• SUCCESSFUL INSPECTION OF FACILITY IN SEPTEMBER 2025

Source text: ID:nBSE7Dpkn3

Further company coverage: INRM.NS

(([email protected];))

Sept 19 (Reuters) - Indoco Remedies Ltd INRM.NS:

• USFDA COMPLETES INSPECTION AT INDOCO'S API FACILITY WITH ZERO OBSERVATIONS

• USFDA COMPLETED INSPECTION OF API FACILITY AT PATALGANGA

Source text: ID:nBSE4wlZgZ

Further company coverage: INRM.NS

(([email protected];;))

July 24 (Reuters) - Indoco Remedies Ltd INRM.NS:

• JUNE-QUARTER CONSOL NET LOSS 357.9 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.29 BILLION RUPEES

Source text: ID:nBSE1Ncwkn

Further company coverage: INRM.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS gains 7.4% to 278 rupees, their highest since Feb. 10

** Pharma co's UK unit launches Ticagrelor film-coated tablets - used for treating patients vulnerable to heart attacks, stroke, other hearts diseases - in the UK

** More than 198,500 shares traded, nearly three times the 30-day avg

** Stock down 22% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** India's Indoco Remedies INRM.NS up 2% at 247.56 rupees

** Co gets approval from U.S. Food and Drug Administration (FDA) for Allopurinol tablets, used to prevent or lower uric acid levels in the blood

** Approval to be positive for growth in the U.S. market, says co

** Including session's gains, stock trims 12-month decline to 20.6%

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

** Indoco Remedies INRM.NS slips as much as 6.4% to 216.07 rupees

** Pharma co's clinical research organisation AnaCipher completes 5-day comprehensive U.S. Food and Drug Administration (FDA) inspection

** Facility gets Form 483 - a notice of violations or issues found in co's practices or products, indicating non-compliance with regulations

** Co did not specify the issues found

** INRM last down 3.5%, extending YTD losses to 30.5%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

March 10 (Reuters) - Indoco Remedies Ltd INRM.NS:

• ANACIPHER COMPLETES US FDA INSPECTION

• FACILITY RECEIVED ONE FORM 483 AT END OF INSPECTION

Source text: ID:nBSE5XTyjs

Further company coverage: INRM.NS

(([email protected];;))

Feb 12 (Reuters) - Indoco Remedies Ltd INRM.NS:

• GETS NOTICE FOR POTENTIAL TAX DEMAND OF 85 MILLION RUPEES

Source text: ID:nBSE34Vz9y

Further company coverage: INRM.NS

(([email protected];;))

** Shares of pharmaceutical co Indoco Remedies Ltd INRM.NS fall ~11% to 304 rupees, set for biggest one-day pct decline since January 2023

** Prabhudas Lilladher downgrades stock to 'hold' from 'accumulate', raises PT slightly to 325 rupees from 320 rupees

** Brokerage says Q3 U.S. sales were impacted by warning letter from FDA for a manufacturing plant in Goa

** Says, FY26 and FY27 margins to be hit by lower sales across regulated markets and ongoing remediation costs in relation to the letter

** INRM's headcount and repair & maintenance expenses will remain elevated - brokerage

** Cuts FY26 EPS estimate by 74.3% to 3.2 rupees and FY27 EPS estimate by 23.5% to 12.5 rupees

** Stock rated 'hold' on avg by 3 analysts, with median PT at 325 rupees- LSEG data

** Stock down 17.5% in last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Jan 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• DEC-QUARTER CONSOL NET LOSS 263.9 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.02 BILLION RUPEES

Source text: ID:nBSEv9z6N

Further company coverage: INRM.NS

(([email protected];;))

Dec 17 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - WARNING LETTER FROM USFDA FOR GOA FACILITY

• INDOCO REMEDIES - CONTINUE TO SUPPLY PRODUCTS FROM GOA FACILITY

Source text: ID:nBSE4zQYKc

Further company coverage: INRM.NS

(([email protected];))

Dec 3 (Reuters) - Indoco Remedies Ltd INRM.NS:

• GOT TAX ORDER WITH POTENTIAL DEMAND OF 155.1 MILLION RUPEES

Source text: ID:nBSE83vkj6

Further company coverage: INRM.NS

(([email protected];;))

Dec 2 (Reuters) - Indoco Remedies Ltd INRM.NS:

• ANNOUNCES STRATEGIC DISTRIBUTION PARTNERSHIP WITH CLARITY PHARMA, UK

• WILL LAUNCH AROUND 20 PRODUCTS OVER NEXT 18 MONTHS THROUGH CLARITY PHARMA

• WILL LAUNCH AROUND 20 PRODUCTS OVER 18 MONTHS THROUGH CLARITY PHARMA IN UK

• WILL CONTINUE TO SUPPLY ALL PRODUCTS UNDER EXISTING B2B PARTNERSHIP TO CLIENTS

Source text: ID:nBSE6S0M60

Further company coverage: INRM.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS rise as much as 5% to 317.50 rupees

** Co gets U.S. FDA approval for varenicline tablets, which are used to help quit smoking

** INRM last up about 2%, set to snap nine-session losing streak

** Stock still down ~22% so far this year, on track for third straight year of losses

** YTD, peers Pfizer Ltd PFIZ.NS and Ajanta Pharma AJPH.NS up ~20% and ~43%, respectively

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Oct 24 (Reuters) - Indoco Remedies Ltd INRM.NS:

• SEPT-QUARTER CONSOL NET LOSS 95.7 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.31 BILLION RUPEES

Source text for Eikon: ID:nnAPN2BSNML

Further company coverage: INRM.NS

(([email protected];;))

Oct 11 (Reuters) - Indoco Remedies Ltd INRM.NS:

• USFDA DETERMINS INSPECTION CLASSIFICATION OF GOA FACILITY OFFICIAL ACTION INDICATED

Source text for Eikon: ID:nBSE5wncb0

Further company coverage: INRM.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS rise as much as 3.3% to 350.70 rupees

** Pharmaceutical co says it has received final approval from the U.S. FDA for an abbreviated new drug application (ANDA) for cetirizine hydrochloride tablets

** Cetirizine is used for relief from symptoms of hay fever and other allergic conditions

** Adds, cetirizine hydrochloride tablets will be manufactured at co's Goa facility

** Avg rating of three analysts equivalent of "buy", median PT is 338 rupees - LSEG data

** Stock last up 2%, cutting YTD loss to 12.4%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Indoco Remedies INRM.NS rise 4.6%

** Pharma co gets U.S. FDA approval for drug used to treat acute opioid withdrawal syndrome

** INRM set for third straight session of gains

** Traded vol of more than 820,000 shares is 8x the 30-day avg; stock's busiest session since mid January - LSEG data

** Stock down ~15% YTD, had fallen ~3% in 2023 for second straight year of losses

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

July 23 (Reuters) - Indoco Remedies Ltd INRM.NS:

• JUNE-QUARTER CONSOL NET PROFIT 26.2 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.24 BILLION RUPEES

Source text for Eikon: ID:nBSE92PYtL

Further company coverage: INRM.NS

(([email protected];))

** Shares of Indoco Remedies INRM.NS climb 2.5% to 318 rupees

** Co gets tentative abbreviated new drug application approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

** Drugs used to treat type 2 diabetes mellitus

** INRM set for a second session of gains, if trend holds

** Stock down ~19.5% so far this year

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

May 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - RECEIVES FINAL ANDA APPROVAL FROM USFDA FOR PREGABALIN CAPSULES

• INDOCO REMEDIES LTD - PREGABALIN CAPSULES WILL BE MANUFACTURED BY CO AT GOA

Source text for Eikon: ID:nBSEbsFHD4

Further company coverage: INRM.NS

(([email protected];))

** Shares of pharmaceuticals company Indoco Remedies INRM.NS fall 2% to 321 rupees

** Co reports a 12% fall in Q4 net profit as costs surge

** Stock opened 1.2% higher ahead of the results, and rose as much as 2.24%

** INRM trading below its 100-day and 200-day simple moving averages since mid-April

** Stock down 2.7% so far in May, eyes fifth consecutive session of falls

($1 = 83.4975 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

March 25 (Reuters) - Indoco Remedies Ltd INRM.NS:

• UNIT WARREN REMEDIES COMMENCED COMMERCIAL PRODUCTION FROM AURANGABAD MANUFACTURING FACILITY

• UNIT COMMENCES COMMERCIAL PRODUCTION OF PHARMACEUTICAL INTERMEDIATES

Source text for Eikon: ID:nBSE553kkm

Further company coverage: INRM.NS

(([email protected];))